This PeerCME symposium took place on 23rd June 2017, as part of the European Hematology Association (EHA) Congress in Madrid, Spain
Chairperson: Paul Cornes1
Speakers: Arnold G. Vulto,2 Wojciech Jurczak3
1. Comparative Outcomes Group, Bristol, UK
2. Erasmus University Medical Centre, Rotterdam, Netherlands
3. Jagiellonian University, Krakow, Poland
Disclosure: Dr Cornes reports salary from the UK NHS, and has received honoraria from Accord Healthcare, Amgen, Bernstein, Biogen, British Medical Journal, European Generics Association, Global Academy of Health Sciences, Hospira/Pfizer, Janssen, Lilly, Merck Serono, Napp, National Cancer Society Malaysia, Pharmaceutical Association of Malaysia, Roche, Sandoz, Synsana EEIG, and Teva. In addition, he has participated in advisory boards for Sandoz and Pfizer. Prof Vulto is a consultant for AbbVie, Biogen, Hospira, Pfizer, and Sandoz. He has been a speaker’s bureau participant with Amgen, Biogen, F. Hoffmann-La Roche Ltd., Febelgen, Medicines for Europe AISBL, and Sandoz. In addition, Prof Vulto has participated in advisory boards for Amgen, Biogen, Boehringer-Ingelheim, and Hexal AG. Prof Jurczak is a consultant for MorphoSys, Novartis & Sandoz, Spectrum, NovoNordisk, Takeda, Teva, and Roche. He has also received research grants from AbbVie, Celltrion, Celgene, Gilead Sciences, Janssen, Pharmacyclics, Pfizer, Novartis & Sandoz, Takeda, Teva, and Roche.
Acknowledgements: Writing assistance was provided by Elizabeth Skinner, ApotheCom, London, UK.
Support: The publication of this article was funded by Sandoz. The views and opinions expressed are those of the speakers and not necessarily Sandoz.
Citation: EMJ Hematol. 2017;5:44-52.
The main objectives of this symposium were to review the value of biosimilars in sustainable treatment for haematologic malignancies and to recognise the developmental differences between biosimilars and their reference products. The meeting also aimed to evaluate the data on monoclonal antibodies for the treatment of haematologic malignancies and the role of biosimilars to address gaps in healthcare. Dr Cornes highlighted recent innovations in cancer treatment and presented biosimilars as economic tools that can address the financial issues that hamper progress. Prof Vulto discussed the need for healthcare professionals to be well informed about the principles of biosimilarity and aware of current and emerging therapies. Prof Jurczak presented the case for rituximab (and its biosimilars) as the standard of care for first-line B cell non-Hodgkin’s lymphoma (NHL) and its potential as maintenance treatment for indolent NHL (iNHL).
Click here to view the full symposium.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
The post Biosimilars for Haematologic Malignancies: The Path to Sustainable Care appeared first on European Medical Journal.